Convidecia Vaccine Side Effects

The Convidecia vaccine is still under clinical trial, and more studies are needed to determine its effectiveness in real-world settings. The trial was limited in its population, mostly people from Mexico and Pakistan, and excluded those with certain health conditions or with children or pregnant women. There is also uncertainty as to how long this vaccine will be effective.


There is little data available on the duration of the risk of thrombocytopenia after Convidecia vaccine (VITT) use. However, patients who develop thrombosis after VITT should be treated with anticoagulation for at least three months. Patients should also be closely monitored for thrombocytopenia for four to 42 days following the vaccination.

A recent study has linked two vaccines to an increased risk of serious blood clots. The CDC suspended the use of the COVID-19 vaccine from Johnson & Johnson (Janssen) due to reports of thrombotic events. These serious blood clots are associated with low platelet levels, which are needed for the formation of blood clots. The condition is known as thrombotic thrombocytopenia syndrome and is caused by several factors, including an inadequate immune response to the vaccine.

PF4 ELISA can help diagnose VITT in post-vaccine patients. If the patient presents with typical lower-extremity VTE and a single low normal value, IVIG may be indicated. The treatment of VITT depends on the type of thrombocytopenia and the underlying cause. If VITT occurs in a patient with pre-existing thrombocytopenia or ITP, IVIG is appropriate.

Two other vaccines are available that do not trigger platelet activation. CanSino Biologics’ Convidecia vaccine and the Gamaleya Institute’s Sputnik V vaccine have not been linked to platelet activation. However, these vaccines use a different adenovirus than J&J’s offering. The manufacturer of both vaccines has tried to distinguish their products in order to minimize the risk of thrombocytopenia.